Immunome (IMNM)
(Delayed Data from NSDQ)
$14.61 USD
+0.61 (4.36%)
Updated Sep 24, 2024 04:00 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for Immunome, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 138 | 20 | 49 | 40 | 3 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 2 | 7 | 3 | 1 |
Total Current Assets | 145 | 23 | 57 | 43 | 3 |
Net Property & Equipment | 2 | 1 | 1 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 149 | 24 | 58 | 45 | 5 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 3 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 5 | 7 | 1 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 10 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 22 | 7 | 10 | 3 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 5 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 7 | 10 | 3 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 39 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 343 | 133 | 127 | 96 | 1 |
Retained Earnings | -223 | -116 | -79 | -54 | -37 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 120 | 17 | 48 | 41 | 3 |
Total Liabilities & Shareholder's Equity | 149 | 24 | 58 | 45 | 5 |
Total Common Equity | 120 | 17 | 48 | 41 | -36 |
Shares Outstanding | 43.20 | 12.10 | 12.10 | 10.50 | NA |
Book Value Per Share | 2.78 | 1.38 | 3.98 | 3.94 | 0.00 |
Fiscal Year End for Immunome, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 278 | 310 | 138 | 91 | 38 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 4 | 7 | 1 | 1 |
Total Current Assets | 284 | 313 | 145 | 91 | 40 |
Net Property & Equipment | 6 | 4 | 2 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 1 | 0 | 0 | 0 |
Total Assets | 296 | 320 | 149 | 93 | 41 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 7 | 3 | 3 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 20 | 11 | 8 | 3 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 13 | 10 | 17 | 18 |
Total Current Liabilities | 40 | 31 | 22 | 23 | 26 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 2 | 5 | 3 | 6 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 1 | 61 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 42 | 34 | 29 | 87 | 32 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 642 | 638 | 343 | 136 | 135 |
Retained Earnings | -388 | -352 | -223 | -130 | -126 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 254 | 286 | 120 | 6 | 9 |
Total Liabilities & Shareholder's Equity | 296 | 320 | 149 | 93 | 41 |
Total Common Equity | 254 | 286 | 120 | 6 | 9 |
Shares Outstanding | 59.90 | 59.90 | 43.20 | 12.20 | 12.20 |
Book Value Per Share | 4.24 | 4.77 | 2.78 | 0.50 | 0.77 |